The study was funded through a grant awarded to Dr. Lewis and Dr. Gorlick by the Kristen Ann Carr Fund (KACF) for the development of a novel treatment for pediatric sarcoma. The study’s objectives were to set the stage for further clinical study in pediatric sarcoma and other childhood cancers. Formed in 1993 in honor of Kristen Ann Carr (1971-1993), the KACF provides funding for the research and treatment sarcoma as well as the education of young physicians through the Kristen Ann Carr Fellowship at the Memorial Sloan-Kettering Cancer Center. Dr. Lewis was the first Kristen Ann Carr Fund Fellow (1993-1995), an honor awarded to him while at Memorial Sloan-Kettering.
Dr. Gorlick commented: “Sarcoma is a disease of high mortality which affects proportionately far more children than adults. It is, therefore, a critical goal of pediatric oncology research to find safer, more effective treatment options for this population. An oral drug could be a breakthrough in pediatric oncology treatment. These early, yet promising, results show the potential of palifosfamide to address this unmet medical need.”
About the Kristen Ann Carr Fund
The Kristen Ann Carr Fund ( www.kristenanncarrfund.org) was formed in 1993, after the death of Kristen Carr, a 21-year-old who was just about to graduate from New York University. It has raised multiple millions for research into this group of rare and deadly tumors, which represent about 15% of all types of cancer in children and about one percent of all types in adults. Kristen Ann Carr Fund projects at Memorial Sloan Kettering Cancer Center include fellowships in both surgery and medical oncology. The KACF also built the Kristen Ann Carr Sarcoma Laboratory, as well as funding many projects in sarcoma and the psycho-social care of teenage and young adult cancer patients throughout the U.S. and internationally.About ZIOPHARM Oncology, Inc.: ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer therapeutics. The Company is currently focused on several clinical programs.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV